Meta-analysis of the risk of upper gastrointestinal hemorrhage with combination therapy of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs

Biological and Pharmaceutical Bulletin

Volumn 37, Issue 6, 2014, Pages 947-953

  Oka, Yoshinari ^a,b   Okamoto, Kousuke ^a   Kawashita, Norihito ^a   Shirakuni, Yuko ^a   Takagi, Tatsuya ^a  

^a OSAKA UNIVERSITY   (Japan)

^b Osaka City Sumiyoshi Hospital   (Japan)

Author keywords

Combination use; Epidemiology; Meta analyses; Non steroidal anti inflammatory drug (NSAID); Selective serotonin reuptake inhibitor (SSRI); Upper gastrointestinal hemorrhage (UGIH)

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; SEROTONIN UPTAKE INHIBITOR;

AGED; ARTICLE; DRUG ANTAGONISM; HUMAN; MANTEL HAENSZEL TEST; META ANALYSIS; PATIENT MONITORING; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT DURATION; UPPER GASTROINTESTINAL BLEEDING; CHEMICALLY INDUCED; DRUG COMBINATION; DRUG INTERACTION; GASTROINTESTINAL HEMORRHAGE; RISK;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; GASTROINTESTINAL HEMORRHAGE; HUMANS; RISK; SEROTONIN UPTAKE INHIBITORS;

EID: 84901830315     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00885     Document Type: Article

References (19)

1. Dalton SO, Johansen C, Mellemkjær L, Nørgård B, Sørensen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch. Intern. Med., 163, 59-64 (2003).
2. Targownik LE, Bolton JM, Metge CJ, Leung S, Sareen J. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am. J. Gastroenterol., 104, 1475-1482 (2009).
3. Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment. Pharmacol. Then, 27, 31-40 (2008).
4. Gasse C, Christensen S, Riis A, Mortensen PB, Adamsen S, Thomsen RW. Preadmission use of SSRIs alone or in combination with NSAIDs and 30-day mortality after peptic ulcer bleeding. Scand. J. Gastroenterol., 44, 1288-1295 (2009).
5. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Stat. Med., 20, 641-654 (2001).
6. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M. Strengthening the reporting of observational studies in epidemiology (STROBE), explanation and elaboration. Epidemiology, 18, 805-835 (2007).
7. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J. Clin. Epidemiol., 62, 1006-1012 (2009).
8. Tata LJ, Fortun PJ, Flubbard RB, Smeeth L, Hawkey CJ, Smith CJ, Whitaker HJ, Farrington CP, Card TR, West J. Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding? Aliment. Pharmacol. Then, 22, 175-181 (2005).
9. de Abajo FJ, García-Rodríguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch. Gen. Psychiatry, 65, 795-803 (2008).
10. Dall M, Schaffalitzky de Muckadell OB, Lassen AT, Hansen JM, Hallas J. An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding. Clin. Gastroenterol. Hepatol., 7, 1314-1321 (2009).
11. Helin-Salmivaara A, Huttunen T, Grönroos JM, Klaukka T, Huupponen R. Risk of serious upper gastrointestinal events with concurrent use of NSAIDs and SSRIs: a case-control study in the general population. Eur. J. Clin. Pharmacol., 63, 403-408 (2007).
12. Lewis JD, Strom BL, Localio AR, Metz DC, Farrar JT, Weinrieb RM, Nessel L, Brensinger C, Kimmel SE. Moderate and high affinity serotonin reuptake inhibitors increase the risk of upper gastrointestinal toxicity. Pharmacoepidemiol. Drug Saf., 17, 328-335 (2008).
13. Zullino DF, Khazaal Y. Increased risk of gastrointestinal adverse effects under SSRI/NSAID combination may be due to pharmacokinetic interactions. Br. J. Clin. Pharmacol., 59, 118-119, author reply, 119 (2005).
14. Mort JR, Aparasu RR, Baer RK. Interaction between selective serotonin reuptake inhibitors and nonsteroidal anti-inflammatory drugs: review of the literature. Pharmacotherapy, 26, 1307-1313 (2006).
15. Wessinger S, Kaplan M, Choi L, Williams M, Lau C, Sharp L, Crowell MD, Keshavarzian A, Jones MP. Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysis. Aliment. Pharmacol. Ther., 23, 937-944 (2006).
16. de Abajo FJ, Rodríguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ, 319, 1106-1109 (1999).
17. De Jong JC, van den Berg PB, Tobi H, de Jong-van den Berg LT. Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects. Br. J. Clin. Pharmacol., 55, 591-595 (2003).
18. Coupland CA, Dhiman P, Barton G, Morriss R, Arthur A, Sach T, Hippisley-Cox J. A study of the safety and harms of antidepressant drugs for older people: a cohort study using a large primary care database. Health Technol. Assess., 15, 1-202 (2011).
19. Yamaguchi T, Hidaka N, Suemaru K, Araki H. The coadministration of paroxetine and low-dose aspirin synergistically enhances gastric ulcerogenic risk in rats. Biol. Pharm. Bull., 31, 1371-1375 (2008).